Opinion|Videos|April 29, 2024

Rentschler Biopharma: A 50-year Legacy of Exceptional CDMO Expertise

Explore how Rentschler Biopharma duels biopharmaceutical innovation, spanning from pioneering biological products to cutting-edge cell and gene therapies

Benedikt von Braunmühl (CEO) and Federico Pollano (vice president of business development) at Rentschler Biopharma explain what sets their CDMO apart. Viewers will learn about:

  • What exceptional CDMO expertise means: 25% of all FDA approved biopharmaceuticals in 2023 were supported by the company
  • Rentschler Biopharma’s US offerings, as well as commercial and development expertise
  • How the company is leveraging its expertise in the field of gene therapy

Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.